Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Merck
Daiichi Sankyo
Fuji
Citi
Express Scripts
McKesson
Baxter
Julphar

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RASAGILINE MESYLATE

« Back to Dashboard

Clinical Trials for Rasagiline Mesylate

Trial ID Title Status Sponsor Phase Summary
NCT00104273 Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed Eisai Inc. Phase 2 The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00104273 Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed Teva Pharmaceutical Industries Phase 2 The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00203034 Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations Completed Teva Pharmaceutical Industries Phase 3 Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
NCT00203060 Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa Completed Teva Neuroscience, Inc. Phase 3 Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
NCT00203138 Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease Completed Teva Pharmaceutical Industries Phase 3 Patients who completed the study TVP-1012/232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinson's disease (PD). During this study the patient's safety, tolerability of rasagiline, and effectiveness of this therapy will be monitored.
NCT00203164 Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients Completed Teva Pharmaceutical Industries Phase 3 This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
NCT00203177 Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy. Completed Teva Pharmaceutical Industries Phase 3 Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Rasagiline Mesylate

Condition Name

Condition Name for Rasagiline Mesylate
Intervention Trials
Parkinson's Disease 6
Parkinsons's Disease 1
Multiple System Atrophy 1
Dementia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rasagiline Mesylate
Intervention Trials
Parkinson Disease 7
Multiple System Atrophy 1
Atrophy 1
Sleep Wake Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rasagiline Mesylate

Trials by Country

Trials by Country for Rasagiline Mesylate
Location Trials
United States 48
Canada 6
South Africa 3
Israel 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rasagiline Mesylate
Location Trials
California 5
Illinois 4
New York 4
Pennsylvania 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rasagiline Mesylate

Clinical Trial Phase

Clinical Trial Phase for Rasagiline Mesylate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rasagiline Mesylate
Clinical Trial Phase Trials
Completed 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rasagiline Mesylate

Sponsor Name

Sponsor Name for Rasagiline Mesylate
Sponsor Trials
Teva Pharmaceutical Industries 8
Eisai Inc. 1
Technische Universität Dresden 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rasagiline Mesylate
Sponsor Trials
Industry 11
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
Moodys
Accenture
Mallinckrodt
Queensland Health
Fish and Richardson
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.